Free Trial
NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
INSY stock logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

INSY Stock News Headlines

Aldeyra Therapeutics, Inc. (ALDX)
Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
See More Headlines
Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2019
Today
7/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

Net Income
$-124,510,000.00
Net Margins
-346.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$82.08 million
Book Value
($0.58) per share

Miscellaneous

Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Mr. Steven J. Meyer (Age 62)
    Exec. Chairman
  • Mr. Saeed Motahari (Age 53)
    CEO, Pres & Director
  • Mr. Andrew G. Long
    Chief Financial Officer
  • Dr. Danny L. Tuck
    Sr. VP of Quality Operations
  • Mr. Franc Del Fosse (Age 47)
    Sr. VP of Corp. Affairs

INSY Stock Analysis - Frequently Asked Questions

How were INSYS Therapeutics' earnings last quarter?

INSYS Therapeutics, Inc. (NASDAQ:INSY) issued its quarterly earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.33. INSYS Therapeutics's revenue was down 68.1% on a year-over-year basis.

When did INSYS Therapeutics' stock split?

INSYS Therapeutics shares split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

What other stocks do shareholders of INSYS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

This page (NASDAQ:INSY) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners